ICON Public Limited Company (ICLR)

Market Cap	7.71B -51.7%
Revenue (ttm)	8.10B -2.5%
Net Income	599.48M -19.8%
EPS	7.47 -16.8%
Shares Out	76.36M
PE Ratio	13.51
Forward PE	7.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,137,972
Open	104.92
Previous Close	104.09
Day's Range	99.49 - 104.92
52-Week Range	66.57 - 211.00
Beta	1.29
Analysts	Buy
Price Target	194.38 (+92.46%)
Earnings Date	Feb 19, 2026

About ICLR

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: May 15, 1998
• Employees: 41,900
• Stock Exchange: NASDAQ
• Ticker Symbol: ICLR
• Website: https://www.iconplc.com

Financial Performance

In 2024, ICLR's revenue was $8.28 billion, an increase of 1.99% compared to the previous year's $8.12 billion. Earnings were $791.47 million, an increase of 29.26%.

Analyst Summary

According to 13 analysts, the average rating for ICLR stock is "Buy." The 12-month stock price target is $194.38, which is an increase of 92.46% from the latest price.

Price Target

$194.38

(92.46% upside)

Analyst Consensus: Buy